ScioScientific LLC

04/05/2026

Research shows that spreading out elective hospital admissions can reduce overcrowding, improve patient safety, and even lower healthcare costs, a simple operational change with major impact. Read more on this.

This intervention improves patient safety, clinician well-being, and hospital finances simultaneously — a rare alignment of incentives in health care.

04/04/2026

New guidelines are helping to change how endometriosis is diagnosed, moving toward earlier, less invasive detection and faster treatment. This could significantly reduce delays and improve care for millions of women living with chronic pain. Read more on this.

Endometriosis is not just a gynecological disease.

04/03/2026

New research shows pharmaceutical companies paid only a small fraction of their revenue in penalties for doctor kickbacks, raising concerns that current fines may not be enough to change industry behavior. Read more on this.

Drugmakers that were penalized for kickbacks paid only 2.2% of their U.S. revenue generated by selling drugs that were the focus of the alleged violations during the past quarter century.

04/02/2026

New findings show NIH funding cuts are disproportionately affecting women, Black researchers, and early-career scientists, raising concerns about equity and the long-term impact on the future of scientific innovation. Here's more on this.

A new paper shows that women, particularly those early in their careers, have been disproportionately affected by NIH grant terminations.

04/01/2026

The Iran war hasn’t significantly disrupted global drug supply chains yet, but experts warn that prolonged conflict could lead to delays, higher costs, and risks to access for critical medicines. Read more on this.

The escalating war in the Middle East so far has not appreciably disrupted global pharmaceutical supply chains, but it could eventually — affecting prices.

03/31/2026

The FDA has approved a higher‑dose version of Novo Nordisk’s Wegovy for obesity, offering a stronger treatment option that showed greater weight loss in clinical trials. This new dose could expand choices for patients managing their weight as the company works to stay competitive in the market. Here's more on this.

A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.

03/30/2026

A Maryland lawmaker wants drug companies to disclose the health conditions of patients mentioned in ads, aiming to boost transparency after concerns that pharmaceutical marketing may use patient stories without clear context. It’s part of a broader push to make prescription drug advertising more honest and helpful for the public. Read more on this.

A bill introduced in the Maryland legislature would require drugmakers to disclose ties to disease awareness campaigns.

03/29/2026

The FDA and NIH are promoting alternatives to animal testing in drug development, aiming to make research faster, more human‑relevant, and more ethical. This could reshape how new medicines are evaluated and developed.

The HHS has made reducing animal testing a priority over the past year.

03/28/2026

Generic semaglutide is set to become available in India as patents expire, a big step for affordability and access to diabetes and obesity treatment. But experts say current eligibility rules based on BMI were written for Western populations and may miss many South Asian patients at risk, highlighting the need to rethink how we define who benefits most. Read more on this.

Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.

03/27/2026

Researchers have developed technology that lets people with paralysis type using just their minds. This kind of innovation could open new doors for communication and independence for those with severe mobility challenges. Here's more.

https://www.statnews.com/2026/03/16/brain-computer-interface/

03/26/2026

Health care workers are sounding the alarm on “alert fatigue” in hospitals as too many digital warnings can overwhelm clinicians and may put patient safety at risk. It’s a reminder that technology needs to support care without creating overload. Here's more on this.

“We cannot let alarm fatigue silence the response to Kennedy’s and Trump’s destruction,” writes Robert Shpiner.

03/25/2026

The FDA is stepping up enforcement against misleading telehealth marketing of weight-loss drugs, highlighting concerns around transparency, safety, and the role of prescribers behind these platforms.

The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.